Zacks Investment Research upgraded QLT Inc. (USA) (NASDAQ:QLTI) to Hold in a statement released earlier today.
- Updated: September 26, 2016
Yesterday QLT Inc. (USA) (NASDAQ:QLTI) traded -3.16% lower at $1.82. QLTI’s 50-day average is $1.50 and its two hundred day average is $1.57. With the last stock price close up 16.89% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same time period. 95,584 shares of QLTI traded, down from an average trading volume of 202,358
Zacks Investment Research has upgraded QLT Inc. (USA) (NASDAQ:QLTI) to Hold in a report released on 9/26/2016.
Recent Performance Chart
QLT Inc. (USA) has 52 week low of $1.22 and a 52 week high of $3.35 and has a market cap of $0.
More About QLT Inc. (USA) (NASDAQ:QLTI)
QLT Inc. is a biotechnology company. The Company is focused on the development and commercialization of ocular products. The Company's operations consist of clinical development programs focused on its synthetic retinoid, QLT091001, for the treatment of certain age-related and inherited retinal diseases (IRD) caused by retinal pigment epithelium protein 65 (RPE65) and lecithin: retinol acyltransferase (LRAT) gene mutations. QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal. The Company is developing QLT091001 for the treatment of IRD caused by RPE65 and LRAT gene mutations, which indication includes Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP). It has completed a Phase Ib clinical proof of concept study and a follow-up retreatment study in LCA and RP patients with autosomal recessive mutations in RPE65 or LRAT, and a Phase 1b study in RP patients with autosomal dominant mutations in RPE65.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.